The Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023.
The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
Rising Global Cancer Epidemics
Advances in Linking Technologies Re-Instills Hope in ADC
Efforts towards Patent Protection to Drive ADC Market
Increasing Demand for Antibody Drug Conjugates
Production Hurdles and Cost
Inadequacy of Experienced Manufacturers
Key Topics Covered:
1. Research View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. Global Antibody Drug Conjugates Market Outlook to 2023
5. Commercialized Antibody Drug Conjugates
6. Antibody Drug Conjugates Pipeline Analysis
7. Drivers and Challenges
8. Major Potential Antibody Drug Conjugates in Pipeline
9. Trends and Developments
10. Strategic Alliances in the Global Antibody Drug Conjugates Industry